Clinical Trials

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT07222631 2026-03-05

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

Phase 1/2 Recruiting

48 enrolled

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

33 enrolled 17 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

Phase 3 Recruiting

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04002947 2026-02-20

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

132 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

438 enrolled

Lymphoma, Non-Hodgkin, Recurrence

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1 Recruiting

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06563596 2026-02-19

Epco, Zanu, Ritux for R/R FL or MZL

45 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05998642 2026-02-12

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

30 enrolled

Lymphoma, Non-Hodgkin

NCT06230224 2026-02-06

OLYMPIA-4

Phase 3 Recruiting

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04965493 2026-01-29

BRUIN CLL-322

LymphoidOther hematologic neoplasm

600 enrolled

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 2 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05023980 2026-01-22

BRUIN CLL-313

LymphoidOther hematologic neoplasm

309 enrolled

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05737628 2026-01-16

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Phase 1 Active not recruiting

17 enrolled